today show glp 1 Generic weight loss drugs to come off the market: What to know The GLP-1 Era Invites Brands

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

With just []

Eli Lilly has just launched its newly approved GLP-1 product, Zepbound, in a direct-to-consumer approach

Evaluate projects that GLP-1 obesity drugs, like Wegovy and Mounjaro, are set to drive record prescription drug sales growth by 2030.

Randomized controlled trials were searched in EMBASE, MEDLINE, CENTRAL, and ClinicalTrials.gov

Learn what evidence shows about colorectal cancer risk.